| The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets B Allard, MS Longhi, SC Robson, J Stagg Immunological reviews 276 (1), 121-144, 2017 | 912 | 2017 |
| Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs B Allard, S Pommey, MJ Smyth, J Stagg Clinical Cancer Research 19 (20), 5626-5635, 2013 | 512 | 2013 |
| The adenosine pathway in immuno-oncology B Allard, D Allard, L Buisseret, J Stagg Nature Reviews Clinical Oncology 17 (10), 611-629, 2020 | 441 | 2020 |
| Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses PA Beavis, N Milenkovski, MA Henderson, LB John, B Allard, S Loi, ... Cancer immunology research 3 (5), 506-517, 2015 | 321 | 2015 |
| Immunosuppressive activities of adenosine in cancer B Allard, PA Beavis, PK Darcy, J Stagg Current opinion in pharmacology 29, 7-16, 2016 | 312 | 2016 |
| Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor D Mittal, A Young, K Stannard, M Yong, MWL Teng, B Allard, J Stagg, ... Cancer research 74 (14), 3652-3658, 2014 | 283 | 2014 |
| CD73 expression is an independent prognostic factor in prostate cancer BG Leclerc, R Charlebois, G Chouinard, B Allard, S Pommey, F Saad, ... Clinical Cancer Research 22 (1), 158-166, 2016 | 219 | 2016 |
| Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects J Stagg, B Allard Therapeutic advances in medical oncology 5 (3), 169-181, 2013 | 219 | 2013 |
| Anti‐CD73 therapy impairs tumor angiogenesis B Allard, M Turcotte, K Spring, S Pommey, I Royal, J Stagg International journal of cancer 134 (6), 1466-1473, 2014 | 193 | 2014 |
| Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, ... Annals of oncology 29 (4), 1056-1062, 2018 | 191 | 2018 |
| Targeting the CD73-adenosine axis in immuno-oncology D Allard, P Chrobak, B Allard, N Messaoudi, J Stagg Immunology letters 205, 31-39, 2019 | 159 | 2019 |
| CD73–adenosine: a next-generation target in immuno-oncology D Allard, B Allard, PO Gaudreau, P Chrobak, J Stagg Immunotherapy 8 (2), 145-163, 2016 | 151 | 2016 |
| CD73‐generated adenosine: orchestrating the tumor‐stroma interplay to promote cancer growth B Allard, M Turcotte, J Stagg BioMed Research International 2012 (1), 485156, 2012 | 134 | 2012 |
| On the mechanism of anti-CD39 immune checkpoint therapy D Allard, B Allard, J Stagg Journal for immunotherapy of cancer 8 (1), e000186, 2020 | 112 | 2020 |
| A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment M Mediavilla-Varela, J Castro, A Chiappori, D Noyes, DC Hernandez, ... Neoplasia 19 (7), 530-536, 2017 | 94 | 2017 |
| Targeting the adenosine pathway for cancer immunotherapy A Hammami, D Allard, B Allard, J Stagg Seminars in Immunology 42, 101304, 2019 | 79 | 2019 |
| Immuno-oncology-101: overview of major concepts and translational perspectives B Allard, S Aspeslagh, S Garaud, FA Dupont, C Solinas, M Kok, B Routy, ... Seminars in cancer biology 52, 1-11, 2018 | 78 | 2018 |
| 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer MK Kilgour, S MacPherson, LG Zacharias, AE Ellis, RD Sheldon, EY Liu, ... Science Advances 7 (4), eabe1174, 2021 | 66 | 2021 |
| Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer B Allard, M Turcotte, J Stagg Expert opinion on therapeutic targets 18 (8), 863-881, 2014 | 65 | 2014 |
| CD73 inhibits cGAS–STING and cooperates with CD39 to promote pancreatic cancer C Jacoberger-Foissac, I Cousineau, Y Bareche, D Allard, P Chrobak, ... Cancer immunology research 11 (1), 56-71, 2023 | 47 | 2023 |